君实生物JS212临床试验申请获受理

财中社
08 Jan

财中社1月8日电君实生物(688180/01877)发布自愿披露公告,宣布其注射用JS212的临床试验申请已获得国家药品监督管理局的受理通知书。该药物是一种重组人源化抗表皮生长因子受体和人表皮生长因子受体3的双特异性抗体偶联药物,主要用于治疗晚期恶性实体瘤。JS212在临床前研究中显示出与EGFR和HER3的高亲和力和特异性结合,且在多个动物模型中展示了显著的抑瘤作用,同时具备良好的安全性。然而,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10